Adaptimmune Therapeutics plc
Adaptimmune Therapeutics plc (ADAP) Revenue
Annual & quarterly revenue history · segment & region breakdown
ADAP · revenue · updated Jun 8, 2026
Core revenue metrics
Trailing 12 monthsAdaptimmune Therapeutics plc trailing twelve-month (TTM) revenue is $0.07B, an increase of 195.34% year-over-year from $0.18B in FY2024.
Revenue trend
2024 – 2013 · AnnualRevenue history
| Fiscal year end | Revenue | Change | Growth |
|---|---|---|---|
| 2024-12-31 | $0.18B | +$0.12B | +195.34% |
| 2023-12-31 | $0.06B | +$0.03B | +122.05% |
| 2022-12-31 | $0.03B | +$0.02B | +341.50% |
| 2021-12-31 | $0.01B | +$0.00B | +55.36% |
| 2020-12-31 | $0.00B | +$0.00B | +252.76% |
| 2019-12-31 | $0.00B | -$0.06B | -98.11% |
| 2018-12-31 | $0.06B | +$0.02B | +57.28% |
| 2017-12-31 | $0.04B | +$0.02B | +166.47% |
| 2016-12-31 | $0.01B | +$0.00B | +32.43% |
| 2015-06-30 | $0.01B | +$0.01B | +1673.22% |
Revenue breakdown
Segment & GeographyAbout Revenue & Reporting
Revenue (also called sales, net sales, or turnover) is the total income Adaptimmune Therapeutics plc receives from its business operations before deducting any costs or expenses. It is the top line of the income statement. Unlike net income or earnings, revenue does not account for operating costs, taxes, interest, or depreciation.
Adaptimmune Therapeutics plc reports revenue on a fiscal year ending Dec 31 basis under US GAAP, denominated in USD.
Data sourced from Adaptimmune Therapeutics plc's 10-K and 10-Q SEC filings via Financial Modeling Prep.
Frequently asked questions
ADAP revenue · 4 questionsADAP's trailing twelve-month (TTM) revenue is $0.07B. That is an increase of 195.34% year-over-year from $0.18B in FY2024.
▸ Source: FMP · Adaptimmune Therapeutics plc SEC filings · GAAP · Adaptimmune Therapeutics plc SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026